Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results